Search

Your search keyword '"E. von Guggenberg"' showing total 83 results

Search Constraints

Start Over You searched for: Author "E. von Guggenberg" Remove constraint Author: "E. von Guggenberg"
83 results on '"E. von Guggenberg"'

Search Results

1. Abstracts of the 33rd International Austrian Winter Symposium

3. Preclinical Evaluation of In-111 and Ga-68 Labelled Minigastrin Analogues for CCK-2 Receptor Imaging

4. Individualized peptide-related-radionuclide-therapy concept using different radiolabelled somatostatin analogs in advanced cancer patients

5. 99mTc-labelled HYNIC-minigastrin with reduced kidney uptake for targeting of CCK-2 receptor-positive tumours

6. 99mTc-labeling and in vitro and in vivo evaluation of HYNIC- and (Nalpha-His)acetic acid-modified [D-Glu1]-minigastrin

7. Comparison of the binding and internalization propertiesof 12 DOTA-coupled and 111In-labelled CCK2/gastrinreceptor binding peptides: a collaborative projectunder COST Action BM0607

8. Safety, Biodistribution, and Radiation Dosimetry of the 68 Ga-Labeled Minigastrin Analog DOTA-MGS5 in Patients with Advanced Medullary Thyroid Cancer and Other Neuroendocrine Tumors.

9. Radiopharmaceutical formulation and preliminary clinical dosimetry of [ 177 Lu]Lu-DOTA-MGS5 for application in peptide receptor radionuclide therapy.

10. Efficacy and safety of rechallenge with [ 177 Lu]Lu-PSMA-I&T radioligand therapy in metastatic castration resistant prostate cancer.

11. Comparison of Two Chelator Scaffolds as Basis for Cholecystokinin-2 Receptor Targeting Bimodal Imaging Probes.

12. Cholecystokinin-2 receptor targeting by [ 68 Ga]Ga-DOTA-MGS5 PET/CT in a patient with extensive disease small cell lung cancer.

13. Automated production of [ 68 Ga]Ga-DOTA-exendin-4 via fractionated radionuclide generator elution on a cassette based synthesis module.

14. Preliminary Clinical Experience with Cholecystokinin-2 Receptor PET/CT Using the 68 Ga-Labeled Minigastrin Analog DOTA-MGS5 in Patients with Medullary Thyroid Cancer.

15. Improved quality control of [ 177 Lu]Lu-PSMA I&T.

16. Effect of N -Terminal Peptide Modifications on In Vitro and In Vivo Properties of 177 Lu-Labeled Peptide Analogs Targeting CCK2R.

17. Effects of Side Chain and Peptide Bond Modifications on the Targeting Properties of Stabilized Minigastrin Analogs.

18. Automated Synthesis of 68 Ga-Labeled DOTA-MGS8 and Preclinical Characterization of Cholecystokinin-2 Receptor Targeting.

20. Update on Preclinical Development and Clinical Translation of Cholecystokinin-2 Receptor Targeting Radiopharmaceuticals.

21. Early Injection of Furosemide Increases Detection Rate of Local Recurrence in Prostate Cancer Patients with Biochemical Recurrence Referred for 68 Ga-PSMA-11 PET/CT.

22. Comparison of Early Imaging and Imaging 60 min Post-Injection after Forced Diuresis with Furosemide in the Assessment of Local Recurrence in Prostate Cancer Patients with Biochemical Recurrence Referred for 68Ga-PSMA-11 PET/CT.

23. Radiopharmaceutical Formulation and Preclinical Testing of 68 Ga-Labeled DOTA-MGS5 for the Regulatory Approval of a First Exploratory Clinical Trial.

24. A New Turn in Peptide-Based Imaging Agents: Foldamers Afford Improved Theranostics Targeting Cholecystokinin-2 Receptor-Positive Cancer.

25. Comparison of PET/CT imaging with [ 18 F]FDOPA and cholecystokinin-2 receptor targeting [ 68 Ga]Ga-DOTA-MGS5 in a patient with advanced medullary thyroid carcinoma.

26. Impact of forced diuresis with furosemide and hydration on the halo artefact and intensity of tracer accumulation in the urinary bladder and kidneys on [ 68 Ga]Ga-PSMA-11-PET/CT in the evaluation of prostate cancer patients.

27. Stabilization Strategies for Linear Minigastrin Analogues: Further Improvements via the Inclusion of Proline into the Peptide Sequence.

29. The 68 Ga/ 177 Lu-theragnostic concept in PSMA-targeting of metastatic castration-resistant prostate cancer: impact of post-therapeutic whole-body scintigraphy in the follow-up.

31. Comparison of PEGylated and non-PEGylated proticles: An in vitro and in vivo study.

32. DOTA-MGS5, a New Cholecystokinin-2 Receptor-Targeting Peptide Analog with an Optimized Targeting Profile for Theranostic Use.

35. Cholecystokinin-2 Receptor Targeting with Novel C-terminally Stabilized HYNIC-Minigastrin Analogs Radiolabeled with Technetium-99m.

36. A novel CCK2/gastrin receptor-localizing radiolabeled peptide probe for personalized diagnosis and therapy of patients with progressive or metastatic medullary thyroid carcinoma: a multicenter phase I GRAN-T-MTC study.

37. Comparison of [ 68 Ga]Ga-PSMA-11 PET/CT with [ 18 F]NaF PET/CT in the evaluation of bone metastases in metastatic prostate cancer patients prior to radionuclide therapy.

38. Multimerization results in formation of re-bindable metabolites: A proof of concept study with FSC-based minigastrin imaging probes targeting CCK2R expression.

39. Site-specific stabilization of minigastrin analogs against enzymatic degradation for enhanced cholecystokinin-2 receptor targeting.

40. Exploiting the Concept of Multivalency with 68 Ga- and 89 Zr-Labelled Fusarinine C-Minigastrin Bioconjugates for Targeting CCK2R Expression.

41. 177 Lu Labeled Cyclic Minigastrin Analogues with Therapeutic Activity in CCK2R Expressing Tumors: Preclinical Evaluation of a Kit Formulation.

42. Early PET imaging with [68]Ga-PSMA-11 increases the detection rate of local recurrence in prostate cancer patients with biochemical recurrence.

43. Developing Targeted Hybrid Imaging Probes by Chelator Scaffolding.

44. 68 Ga-PSMA-11 PET/CT in primary staging of prostate cancer: PSA and Gleason score predict the intensity of tracer accumulation in the primary tumour.

45. Early dynamic imaging in 68 Ga- PSMA-11 PET/CT allows discrimination of urinary bladder activity and prostate cancer lesions.

46. Methoxinine - an alternative stable amino acid substitute for oxidation-sensitive methionine in radiolabelled peptide conjugates.

47. Current knowledge on the sensitivity of the (68)Ga-somatostatin receptor positron emission tomography and the SUVmax reference range for management of pancreatic neuroendocrine tumours.

48. Preclinical pharmacokinetics, biodistribution, radiation dosimetry and toxicity studies required for regulatory approval of a phase I clinical trial with (111)In-CP04 in medullary thyroid carcinoma patients.

49. Influence of a novel, versatile bifunctional chelator on theranostic properties of a minigastrin analogue.

50. Multiparametric PET imaging in thyroid malignancy characterizing tumour heterogeneity: somatostatin receptors and glucose metabolism.

Catalog

Books, media, physical & digital resources